Ara
Toplam kayıt 1, listelenen: 1-1
Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey
(Elsevier Science Inc, 2019)
[No Abstract Available]
Toplam kayıt 1, listelenen: 1-1